#400 Antiplatelets, Anticoagulation for Coronary Artery Disease and Afib
The Curbsiders Internal Medicine Podcast
00:00
The Future of P2Y12 Inhibitors
There are five trials now looking at stopping the aspirin instead of the P2Y12. That's mostly not in patients with AFib. But some of that we do see in patients withAFib as well. E2Y12s, again, give us benefit over aspirin in terms of reducing ischemic events. And in general, they're better than aspirin interms of bleeding as well. So win-win.
Transcript
Play full episode
